A new class of antiemetics: the NK-1 receptor antagonists

被引：9

作者：

Bleiberg, H ^{[1
]}

机构：

[1] Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium

来源：

CURRENT OPINION IN ONCOLOGY | 2000年 / 12卷 / 04期

关键词：

D O I：

10.1097/00001622-200007000-00002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Emesis is one of the most unpleasant and debilitating side effects of anticancer chemotherapy. In acute emesis (vomiting occurring 0-24 hours after chemotherapy administration), the 5-HT3 receptor antagonists and corticosteroids are highly effective, with few significant side effects, and can safely be combined. Delayed emesis (vomiting occurring >24 hours after chemotherapy administration), however, is both not well understood and less well controlled. Studies have yielded conflicting results concerning the use of 5-HT3 receptor antagonists alone in delayed emesis. The data of NK-1 receptor antagonists in the control of acute emesis, although promising, need confirmation in a properly designed study. Curr Opin Oncol 2000, 12:284-288 (C) 2000 Lippincott Williams & Wilkins, Inc.

引用

页码：284 / 288

页数：5

共 21 条

[1] ANTIEMETIC PROFILE OF A NONPEPTIDE NEUROKININ-NK(1) RECEPTOR ANTAGONIST, CP-99,994, IN FERRETS [J].

BOUNTRA, C ;

BUNCE, K ;

DALE, T ;

GARDNER, C ;

JORDAN, C ;

TWISSELL, D ;

WARD, P .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 249 (01) :R3-R4

[2] The substance P receptor antagonist CP-99,994 reduces acute postoperative pain [J].

Dionne, RA ;

Max, MB ;

Gordon, SM ;

Parada, S ;

Sang, C ;

Gracely, RH ;

Sethna, NF ;

MacLean, DB .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (05) :562-568

[3] The site of the anti-emetic action of tachykinin NK1 receptor antagonists may exist in the medullary area adjacent to the semicompact part of the nucleus ambiguus [J].

Fukuda, H ;

Nakamura, E ;

Koga, T ;

Furukawa, N ;

Shiroshita, Y .

BRAIN RESEARCH, 1999, 818 (02) :439-449

[4] Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines [J].

Gralla, RJ ;

Osoba, D ;

Kris, MG ;

Kirkbride, P ;

Hesketh, PJ ;

Chinnery, LW ;

Clark-Snow, R ;

Gill, DP ;

Groshen, S ;

Grunberg, S ;

Koeller, JM ;

Morrow, GR ;

Perez, EA ;

Silber, JH ;

Pfister, DG .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2971-2994

[5] IMMUNOHISTOCHEMICAL STUDY OF NEUROPEPTIDES IN VAGAL AND GLOSSOPHARYNGEAL AFFERENT NEURONS IN THE RAT [J].

HELKE, CJ ;

HILL, KM .

NEUROSCIENCE, 1988, 26 (02) :539-551

[6] Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis [J].

Hesketh, PJ ;

Gralla, RJ ;

Webb, RT ;

Ueno, W ;

DelPrete, S ;

Bachinsky, ME ;

Dirlam, NL ;

Stack, CB ;

Silberman, SL .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :338-343

[7] TACHYKININ RECEPTORS IN GASTROINTESTINAL MOTILITY [J].

HOLZERPETSCHE, U .

REGULATORY PEPTIDES, 1995, 57 (01) :19-42

[8] NEURONS IN THE NUCLEUS OF THE SOLITARY TRACT MEDIATING INPUTS FROM EMETIC VAGAL AFFERENTS AND THE AREA POSTREMA TO THE PATTERN GENERATOR FOR THE EMETIC ACT IN DOGS [J].

KOGA, T ;

FUKUDA, H .

NEUROSCIENCE RESEARCH, 1992, 14 (03) :166-179

[9] Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin [J].

Kris, MG ;

Radford, JE ;

Pizzo, BA ;

Inabinet, R ;

Hesketh, A ;

Hesketh, PJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (11) :817-818

[10]

Machover D, 1996, ANN ONCOL, V7, P95

← 1 2 3 →